Analisis Perbedaan Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Coronavac Dosis Pertama dan Kedua pada Masyarakat Provinsi Jawa Tengah

Arifin Santoso(1*), Indriyati Hadi Sulistyaningrum(2), Fildza Huwaina Fathnin(3), Atma Rulin Dewi Nugrahaeni(4), Abdur Rosyid(5), Syifa Audina Banin(6)

(1) Bagian Farmasi Klinik dan Komunitas, Program Studi Sarjana Farmasi dan Program Studi Profesi Apoteker, Fakultas Kedokteran, Universitas Islam Sultan Agung, Jl. Kaligawe Raya No. KM 4, Semarang, Indonesia, 50112
(2) Bagian Farmasi Klinik dan Komunitas, Program Studi Sarjana Farmasi dan Program Studi Profesi Apoteker, Fakultas Kedokteran, Universitas Islam Sultan Agung, Jl. Kaligawe Raya No. KM 4, Semarang, Indonesia, 50112
(3) Bagian Farmasi Klinik dan Komunitas, Program Studi Sarjana Farmasi dan Program Studi Profesi Apoteker, Fakultas Kedokteran, Universitas Islam Sultan Agung, Jl. Kaligawe Raya No. KM 4, Semarang, Indonesia, 50112
(4) Bagian Farmasi Klinik dan Komunitas, Program Studi Sarjana Farmasi dan Program Studi Profesi Apoteker, Fakultas Kedokteran, Universitas Islam Sultan Agung, Jl. Kaligawe Raya No. KM 4, Semarang, Indonesia, 50112
(5) Bagian Farmasi Klinik dan Komunitas, Program Studi Sarjana Farmasi dan Program Studi Profesi Apoteker, Fakultas Kedokteran, Universitas Islam Sultan Agung, Jl. Kaligawe Raya No. KM 4, Semarang, Indonesia, 50112
(6) Bagian Farmasi Klinik dan Komunitas, Program Studi Sarjana Farmasi dan Program Studi Profesi Apoteker, Fakultas Kedokteran, Universitas Islam Sultan Agung, Jl. Kaligawe Raya No. KM 4, Semarang, Indonesia, 50112
(*) Corresponding Author

Abstract

Adverse events following immunization (AEFI) for the coronavac vaccine are still widely found in Indonesia, especially in Central Java that happened in the first and second dose. The purpose of this study was to determine the difference between AEFI of the first and second dose of coronavac vaccine among recidents in Central Java. This cross-sectional study used a questionnaire with respondents from the recidents of central Java who carried out the first and second dose of coronavac. Statistical descriptive analysis, then an analysis of the differences of AEFI of the first and second dose of coronavac was carried out with dependent sample t-test. The results showed that the most common AEFI of coronavac were muscle pain at the first dose (11,2%) and the second dose (9,2%), followed by lethargy at the first dose (10,1%) and the second dose (8,3%), then pain accompanied by weakness in the arm injected at the first dose (8,8%) and the second dose (8,6%), and the swelling at the injection site at the first dose (7,5%) and the second dose (7,7%). There was no significant difference between AEFI that occurred after coronavac vaccination at the first and second dose as indicated by p value 0,320 (p >0,05).

Keywords

Covid-19; Coronavac; Adverse events following immunization (AEFI); WHO

Full Text:

PDF

References

Asmara I.G.Y., 2016. Hipersensitivitas Terhadap Vaksin. Jurnal Kedokteran Umum. 5 (3), 39–44.

Basri A.H., 2021. Analisis Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 Sinovac Di Rumah Sakit Wirasakti Kupang Periode 20 Januari 2021 – 20 Februari 2021. Skripsi. Undana.

Desnita R., Sapardi V.S., and Surya D.O., 2022. Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 Dosis Pertama dan Kedua. Jurnal Ilmu Kesehatan, 6 (1), 20–26.

Elgendy M. O., El-Gendy A.O., Mahmoud S., Mohammed T.Y., Abdelrahim M.E.A., and Sayed A.M., 2022. Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population. Vaccines, 10 (1), 7–9.

Fadhlil et al., 2021. Selaksa Harapan di masa Pandemi. Bandar : Publishing. ISBN : 978-623-6114-544. hal : 114-117.

Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E. A., Dold C., Faust S. N., Finn A., Flaxman A. L., Hallis B., Heath P., Jenkin D., Lazarus R., Makinson R., Yau Y., 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, 396 (10249), 467–478.

Goni A.T., Ahmad M., and Karundeng M., 2022. Pengalaman Orang Dengan Hipertensi Terhadap Vaksinasi Covid-19 di Puskesmas Pineleng. Jurnal Keperawatan, 10 (1), 119.

Hafizzanovian H., Oktariana D., Apriansyah M.A., and Yuniza Y., 2021. Peluang Terjadinya Immunization Stress-Related Response (ISRR) Selama Program Vaksinasi Covid-19. Jurnal Kedokteran dan Kesehatan, Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya, 8 (3), 211–222.

Irnawati, Sulistyanto B.A., and Fajriyah N.N., 2021. Management Of Immune Formation for Covid-19 Prevention Through Vaccination. Urecol Journal. Part C:Health Sciences, 1(2), 67–75.

Kementerian Kesehatan RI. 2021. Petunjuk Teknis Pelaksanaan Vaksinasi dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (Covid-19). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/4638/2021.

Khan M.K., Ferdous J., Akhter S., Esha A.M., Islam M. 2022. Tracking Side Effects of the COVID-19 Vaccine in Mymensingh District of Bangladesh. Mymensingh Med J, 31 (1), 1-9. PMID: 34999672.

Novita A., and Ramadhani N.R., 2021. Webinar Vaksinasi Covid-19 untuk Meningkatkan Kesadaran Masyarakat. Shihatuna : Jurnal Pengabdian Kesehatan Masyarakat, 1 (1), 29.

Rakhmadhani I., Yulida E., Fauzan A., and Jaelani A.K., 2022. Adverse Events Following Immunization Post Moderna (mRNA1273) Booster Vaccination after Two Primary Doses of CoronaVac. International Journal of Health Sciences, 6 (1), 160–173.

Sari, M. K. (2021). Edukasi Kejadian Ikutan Pasca Imunisasi Terhadap Tingkat Kecemasan Remaja Menghadapi Vaksinasi Covid-19. 5(3), 542–546.

Simanjorang, C., Surudani, C. J., & Makahaghi, Y. B. (2022). Gambaran Awal Efek Samping Vaksin Sinovac-Coronavac Pada Petugas Kesehatan Di Kabupaten Kepulauan Sangihe. Jurnal Ilmiah Sesebanua, 5(2), 43–47.

Supangat, Sakinah E.N., Nugraha M.Y., Qodar T.S., Mulyono B.W., and Tohari A.I., 2021. COVID-19 Vaccines Programs : Adverse Events Following Immunization (AEFI) Among Medical Clerkship Student in Jember, Indonesia. BMC Pharmacology and Toxicology, 22 (1): 58.

Syariah N, 2022. Prevalence of Adverse Events Following Imunization (AEFI) Incidence of Sinovac Vaccination at Clinic Unismuh Medical Centre. Skripsi. Fakultas Kedokteran dan Ilmu Kesehatan Universitas Muhammadiyah Makassar.

Timur M.S., Community E.S., Nisak L., Suparningtyas J. F., and Kuncoro H., 2021. Proceeding. Mulawarman Pharmaceuticals Conferences. 138–144.

Triyo R., Titi PR., Ari W., and Wakhid Y., 2021. Pemberian Vaksinasi COVID-19 Bagi Masyarakat Kelompok Petugas Pelayanan Publik di Kecamatan Buluspesantren. JURPIKAT (Jurnal Pengabdian Kepada Masyarakat), 2 (2), 104–119.

WHO. 2021. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. World Health Organization, October, 1–9.

Yulyani V., Hasbie N.F., Putri D.F., and Ramadhan, M.Y., 2022. Gambaran Status Demografi, Penyakit Komorbid dan Kejadian Ikutan Pasca Imunisasi (KIPI) pada Tenaga Kesehatan Setelah Vaksin Covid-19 di RSUD Abdul Moeloek. Malahayati Nursing Journal, 4 (6), 1387–1398.

DOI: 10.23917/pharmacon.v19i2.19746

Article Metrics

Abstract view(s): 257 time(s)
PDF: 270 time(s)

Refbacks

  • There are currently no refbacks.